Long-Term Secukinumab in Psoriatic Arthritis
LONG-TERM secukinumab treatment preserved bone structure and controlled disease activity in psoriatic arthritis over 48 months.
New long-term data suggest that IL-17A blockade with secukinumab may offer sustained osteoprotective effects in patients with psoriatic arthritis. In this phase IV non-interventional study, investigators followed adults with active psoriatic arthritis for 48 months using high-resolution peripheral quantitative CT and MRI of the hand to assess structural bone outcomes alongside clinical response.
A total of 32 patients were enrolled, with a mean age of 56 years and 40.6% female representation. Over the 48-month follow-up period, the drug survival rate was 68.8%. Across multiple disease domains, secukinumab was associated with significant improvement in disease activity, enthesitis, skin involvement, patient-reported disease impact, and pain. Functional status, measured using the Health Assessment Questionnaire, remained stable.
Bone Protection With Secukinumab
The most notable finding was the stability of structural bone outcomes over time. On high-resolution peripheral quantitative CT, bone density, cortical and trabecular microarchitecture, and biomechanical properties were preserved throughout follow-up. Investigators also found no significant progression in the number or volume of bone erosion.
MRI findings supported these results. Inflammatory features remained stably low over the study period, suggesting durable suppression of imaging-detected inflammation. Although PsAMRIS subitems for erosion and osteoproliferation increased marginally, the overall imaging pointed to minimal structural progression during long-term secukinumab therapy.
Clinical Relevance for Psoriatic Arthritis Care
These findings are clinically meaningful because structural damage in psoriatic arthritis can lead to long-term disability and impaired quality of life. The study suggests that secukinumab not only improves key manifestations of psoriatic arthritis but may also help maintain bone integrity over several years.
No major safety signals emerged during follow-up. Overall, the imaging and clinical data support the idea that IL-17A inhibition with secukinumab can deliver sustained disease control together with long-term osteoprotective effects in psoriatic arthritis.
Reference
Schuster L et al. Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study. RMD Open. 2026;DOI: 10.1136/rmdopen-2025-005857.
Featured Image: Suslov Denis on Adobe Stock.
